首页|期刊导航|Pharmacoeconomics and Policy|Linked pharmacometrics-pharmacoeconomics model for cost-effectiveness analysis of tacrolimus in liver transplant patients from real-world data

Linked pharmacometrics-pharmacoeconomics model for cost-effectiveness analysis of tacrolimus in liver transplant patients from real-world dataOA

中文摘要

Tacrolimus(TAC)is an essential immunosuppressant for preventing graft failure after liver transplantation,but its narrow therapeutic window,high cost,and metabolism by CYP3A4/3A5 create challenges for in-dividualized dosing.Diltiazem(DTZ),a CYP3A4 inhibitor commonly co-administered for comorbid hy pertension,may increase TAC exposure and thereby reduce the TAC dose required to achieve target con-centrations,potentially lowering treatment costs.This study evaluated the cost-effectiveness of potential TAC/DTZ dosing regimens in liver transplant recipients with hypertension using a linked pharmacometrics-pharmacoeconomics(PMPE)framework.Clinical data from 483 liver transplant cases at a specialist hospital were used to develop a physiologically based pharmacokinetic-pharmacodynamic(PBPK-PD)model that quantified the relationship between TAC trough concentrations(c_(trough))and graft failure risk and supported regimen optimization.A Markov model was then applied to estimate annual costs and graft failure outcomes across candidate regimens.Among the evaluated strategies,the TAC/DTZ 1/30 mg regimen was identified as the most cost-effective option.Cost-effectiveness acceptability curve(CEAC)analysis showed that the opti-mized regimen had a 70.0%probability of being cost-effective at a willingness-to-pay(WTP)threshold of$38,201.These findings suggest that TAC/DTZ combination regimens may be cost-effective in hypertensive liver transplant recipients and demonstrate the feasibility of a linked PMPE model for generating pharma coeconomic(PE)evidence to support clinical and policy decision-making.

Aole Zheng;Wen Yao Maka;Xiaoping Shi;Xinyue Zhang;Jiaqi Ni;Yunrong Shen;Zhen Feng;Donghui Lao;Xiao Zhu;Xiaoqiang Xiang;Qingfeng He

Department of Clinical Pharmacy and Pharmacy Administration,School of Pharmaceutical Sciences,Fudan University,Shanghai,201203,ChinaDepartment of Clinical Pharmacy and Pharmacy Administration,School of Pharmaceutical Sciences,Fudan University,Shanghai,201203,ChinaDepartment of Clinical Pharmacy,Zhongshan Hospital,Fudan University,Shanghai,200032,ChinaDepartment of Clinical Pharmacy and Pharmacy Administration,School of Pharmaceutical Sciences,Fudan University,Shanghai,201203,ChinaWest China School of Pharmacy,Sichuan University,Chengdu,610041,ChinaCollege of Pharmacy,The University of Arizona,Tucson,AZ,85287,USADepartment of Pharmacy,The Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,221006,ChinaDepartment of Clinical Pharmacy,Zhongshan Hospital,Fudan University,Shanghai,200032,ChinaDepartment of Clinical Pharmacy and Pharmacy Administration,School of Pharmaceutical Sciences,Fudan University,Shanghai,201203,ChinaDepartment of Clinical Pharmacy and Pharmacy Administration,School of Pharmaceutical Sciences,Fudan University,Shanghai,201203,ChinaDepartment of Clinical Pharmacy and Pharmacy Administration,School of Pharmaceutical Sciences,Fudan University,Shanghai,201203,China

医药卫生

Pharmacometrics-pharmacoeconomicsPhysiologically-basedpharmacokineticsCost-effectivenessanalysisTacrolimusDiltiazemLivertransplantation

《Pharmacoeconomics and Policy》 2026 (2)

P.110-118,9

supported by Shanghai Municipal Health Commission,China(Grant No.:20234Y0233)the National Natural Science Foundation of China(Grant No.:82204502)Shanghai Pujiang Programme,China(Program No.:23PJD016)Fudan University Talent Start-up Fund,China.

10.1016/j.pharp.2026.06.008

评论